Unknown

Dataset Information

0

Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties.


ABSTRACT: In line with recent clinical trials demonstrating that ondansetron, a 5-HT3 receptor (5-HT3R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT6 receptor (5-HT6R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists. We identified the first-in-class compound FPPQ, which behaves as a 5-HT3R antagonist and a neutral antagonist 5-HT6R of the Gs pathway. FPPQ shows selectivity over 87 targets and decent brain penetration. Likewise, FPPQ inhibits phencyclidine (PCP)-induced hyperactivity and displays procognitive properties in the novel object recognition task. In contrast to FPPQ, neither 5-HT6R inverse agonist SB399885 nor neutral 5-HT6R antagonist CPPQ reversed (PCP)-induced hyperactivity. Thus, combination of 5-HT3R antagonism and 5-HT6R antagonism, exemplified by FPPQ, contributes to alleviating the positive-like symptoms. Present findings reveal critical structural features useful in a rational polypharmacological approach to target 5-HT3/5-HT6 receptors and encourage further studies on dual-acting 5-HT3/5-HT6R antagonists for the treatment of psychiatric disorders.

SUBMITTER: Zajdel P 

PROVIDER: S-EPMC8474115 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8347595 | biostudies-literature
| S-EPMC6493064 | biostudies-literature
| S-EPMC6613932 | biostudies-literature
| S-EPMC10853020 | biostudies-literature
| S-EPMC6891367 | biostudies-literature
| S-EPMC2013955 | biostudies-other
| S-EPMC6072329 | biostudies-literature
| S-EPMC7458427 | biostudies-literature
| S-EPMC8270334 | biostudies-literature
| S-EPMC6648382 | biostudies-literature